Efficacy of tirzepatide does not differ significantly between men and women, despite sex-specific differences in ...

Researchers analysed data from a population-based case-control study linked to the Swedish Rheumatology Quality Register to investigate the association of obesity and/or overweight with the risk for ...

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this glucagon-like peptide-1 receptor agonist has already received for the numerous ...

An updated report on statistics regarding heart failure epidemiology and outcomes has been published by the HFSA.

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...

Please provide your email address to receive an email when new articles are posted on . Wegovy was linked to lower year-to-year health care costs among patients with overweight or obesity and heart ...

LOWCOUNTRY, S.C. (WCIV) — Having trouble sleeping at night? It could very well be sleep apnea. New studies have shown that obesity does not play as significant a role in obstructed sleep apnea as ...

More than 99% of people who experienced a heart attack, heart failure, or stroke had at least one of four major ...

When the workload on the heart increases, the ventricular wall may thicken too, known as cardiac hypertrophy. This is an adaptive response that reduces pressure on the heart and maintains the activity ...